Impact of the COVID-19 pandemic on antiviral drug development for other community-acquired respiratory viruses’ infections

The coronavirus disease 2019 (COVID-19) pandemic indirectly resulted in missed therapeutic opportunities for many diseases. Here we focus on community-acquired respiratory viruses other than severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) [respiratory syncytial virus, parainfluenza and i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghrieb, Zineb, Salmona, Maud, Michonneau, David, De Saisset, Charles, Allaoua, Souhil, Kiladjian, Jean-Jacques, Le Goff, Jérôme, Bergeron, Anne, Benajiba, Lina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Masson SAS on behalf of Société française de pharmacologie et de thérapeutique. 2023
Materias:
Clinical Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9341168/
https://www.ncbi.nlm.nih.gov/pubmed/36030128
http://dx.doi.org/10.1016/j.therap.2022.07.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9341168/
https://www.ncbi.nlm.nih.gov/pubmed/36030128
http://dx.doi.org/10.1016/j.therap.2022.07.010

Ejemplares similares